Demand on Global Small Molecule API Market 2020-2023

 Global Small Molecule API Market – Overview

Development in the small molecule API can be attributed due to the growth observed in the pharmaceutical and chemical sector. Market reports linked to the healthcare sector along with published reports on other sectors have been lately made available by Market Research Future, which has also published a report on this market. The industry for small molecule API is anticipated to grow with a CAGR of 7.0 percent while touching revenues worth $279.7 billion in revenue approximately from 2016 to 2027.

Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/763 

The increasing growth of pharmaceutical sector has been beneficial to the expansion of the small molecule API market. Cardiovascular disorder segment is expected to grow at positively in the forecast period owing to increased consumer demand. The ease of procurement of raw materials has been advantageous to the development of the industry further. The industry is expected to gain momentum with the development of better distribution networks that will accelerate industry growth in the forecast period.

Global Competitive Analysis

The corporate strategy of the competitors in the market is focused currently on capitalizing the dynamic pace of technological innovations which have led to plenty of changes both in terms of product development and handling competition. This particular trend has enabled portfolio improvement along with the affinity for diversification in the sector, which has indirectly enabled the players to use the valuable state of dealings available in this industry. The use of these prospects by contenders, who are trying to cultivate their industry stake by intensive expansion can stimulate the expansion of this industry. The companies are also moreover trying to create and capture financial in a suitable manner. This has elevated the potential for the forthcoming growth period significantly. The strategic decision-making process has increased the productivity of companies so that they maintain their company’s liquidity and sustain feasible to take effective choices in terms of strategy designing and implementation.

A few of the major contenders in this industry are:

• Allergan Plc
• Aurobindo Pharma
• Albemarle Corporation
• Dr. Reddy’s Laboratories Ltd
• Glaxosmithkline Plc
• Cambrex Corporation
• Lonza and more.

Industry Segments 

The Small Molecule API Industry globally has been segmented on the basis of types which include biological API and synthetic/chemical API. On the basis of application the industry is divided into oncology, immunological disorders, cardiovascular, diabetes among others. On the basis of manufacturing method, the industry is divided into contract manufacturing and in-house. 

Detailed Regional Analysis

The small molecule API industry covers five regions majorly such as Latin America, Europe, Asia Pacific, North America, Middle East and Africa. The North American region is the biggest market for the small molecule API industry. The European region is the next largest region for the small molecule API industry. Additionally, the Asia pacific region is estimated to be the most rapidly growing region for small molecule API industry.

Industry Updates:

March 2018 Arcinova, a UK based company, which provides integrated end to end solutions and standalone services to pharmaceutical and biotech companies will now have access to Sterling Pharma Solutions’ scale up and pilot plant assets, which will match the company’s existing abilities. Sterling Pharma Solutions which is also based in UK and is located 28 miles from the Arcinova site. The premises include pilot plant assets that range between 50lt up to 1300lt capacity, with a 5-100kg batch generation capability. The combined service offering will enable Arcinova to ensure technical transfer from grams to 100’s kilogram scale and is intended to guarantee an integrated premises to meet their clients’ drug substance requests, from preclinical up to full scale commercial launch stages. Sterling Pharma Solutions is a provider of small molecule API development and services to the pharmaceutical industry globally.

Check Discount at https://www.marketresearchfuture.com/check-discount/763 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com 

NEWS: Spirometry Market Size, Trends and Global Demand

 Spirometry Market Overview:

The global spirometry market is expecting to touch a valuation of USD 1,106.46 million by 2023, according to Market Research Future (MRFR).  The high prevalence of respiratory disorders is the major factor driving the market growth from 2018 to 2023 (forecast period). Rising cases of chronic obstructive pulmonary disorders (COPD), technological advances in respiratory care devices, and the expanding geriatric population are factors expected to spur market demand till 2023. As per a report by Asthma UK in 2016, nearly 1,410 people died from asthma.

Get Request Free Sampl @ https://www.marketresearchfuture.com/sample_request/6539

Government initiatives to curtail smoking habits, focus on breathing diseases, rising levels of air pollution, and adoption of spirometers at homes are factors likely to augur market growth. Awareness of reimbursement policies among the public and clinicians are projected to drive patients towards taking these tests. But high costs of spirometers can act as a deterrent against market growth.

Spirometry MarketCompetitive Dashboard:

Key players in the spirometry market include Smiths Medical Inc. (U.S.), Vitalograph (U.K.), MGC Diagnostics Corporation (U.S.), Hill-Rom Holdings, Inc. (U.S.), Schiller AG (Switzerland), COSMED srl (Italy), Midmark Corporation (U.S.), NDD Medical Technologies, Inc. (U.S.), Carefusion Corporation (U.S.), Nihon Kohden Corporation (Germany), and Koninklijke Philips N.V. (The Netherlands).

Spirometry Market Segmentation:

The spirometry market can be segmented by product, technology, application, and end-user.

By product, the market is segmented into table-top spirometry, hand-held spirometry, and desktop (PC) spirometry. The table-top spirometry segment accounted for 49.9% market share in 2017, followed by hand-held (31%), and desktop (19.1%). This can be attributed to adoption of spirometers in hospitals and clinics. But the desktop segment is touted to register the highest CAGR of 10.58% during the forecast period owing to its rapid diagnosis rate and increasing use of computer-based applications.

By technology, the market covers flow measurement spirometry, volume spirometry, and peak flow meters (PFM). The flow measurement spirometry segment accounted for 50.3% share in 2017. This can be attributed to its lightweight nature and compact size. Its functionality based on the familiar table-top spirometer technology and lack of frequent calibration make it popular among clinicians. But the PFM technology can register 10.58% CAGR over the forecast period to reach USD 149.76 million by 2023.

Major applications of the spirometry market include diagnostic and treatment monitoring. The diagnostic segment is further sub-segmented into asthma, interstitial pulmonary fibrosis, and COPD. The diagnostic segment accounted for 68.93% share of the market in 2017, spurred by the prevalence of breathing diseases such as asthma. But the treatment monitoring segment can exhibit the highest CAGR during the review period to reach a valuation of USD 353 million by 2023. Its valuation in 2018 was suggested to be USD 214.12 million.

Key market end-users include hospitals & clinics, research & academic institutes, diagnostic centers, and home care. The home care segment is projected to enjoy a 9.90% CAGR to reach a valuation of USD 71.14 million by 2023 from USD 44.38 million in 2018.

Spirometry Market Regional Analysis:

The spirometry market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas accounted for 39.74% share in the global market in 2017, followed by Europe and APAC. This can be attributed to economies such as the U.S. which are the earliest adopters of latest technologies coupled with the large patient pool suffering from respiratory disorders. The region is likely to enjoy a 10.25% CAGR over the forecast period.

The Europe spirometry market is expected to enjoy a CAGR similar to the Americas market over the forecast period to touch a valuation of USD 322.33 million by 2023. This can be credited to rising number of asthma cases and ballooned healthcare expenditure of nations such as Germany and France.

The MEA region can experience a respectable CAGR during the review period owing to improvements of healthcare infrastructure and enhanced healthcare budgets of Kuwait, Qatar, and Dubai.

The APAC region is expected to exhibit a 10.94% CAGR over the forecast period owing to high cases of chronic diseases, awareness of respiratory devices, and increased healthcare budgets of developed nations in the region. The growing geriatric populace in China and Japan can contribute to regional market revenue till 2023.

Access Report @ https://www.marketresearchfuture.com/reports/spirometry-market-6539

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

 MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

 Contact:

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

Latest Research On Myasthenia Gravis Disease Market Size, share and Forecast

 Myasthenia Gravis Disease Market Scenario

Market Research Future (MRFR) proclaims that the global myasthenia gravis disease market is estimated to garner 7.5% CAGR during the forecast period (2017-2023). The surging cases of neuromuscular disorders are estimated to favor the market growth globally. Myasthenia gravis is referred to as a neuromuscular disorder which results in the skeletal muscles to weaken. The disease generally occurs due to the impairment of communication between the nerve cells and the muscles and causes difficulty in the relaxation and contraction of muscles. The antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint which prevents the muscles from contracting and performing its normal function.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/5843

Market Potential and Pitfalls

Myasthenia Gravis can occur both in females and males but usually affect the women under 40 years and the aging population from 50 to 70 years. With surging cases of neuromuscular disorders, a growing number of clinical facilities, and raising awareness regarding the treatment line, the global myasthenia gravis disease is considered to receive a boost. The increasing occurrences of autoimmune disorders, rising spending on healthcare, and a strong pipeline in the treatment are some of the factors contributing to the growth of the market. The surging cases of myasthenia gravis can impact the quality of life, which further fosters its growth. With the growth in R&D activities, the myasthenia gravis disease market is likely to experience a thrust. Moreover, the rising adoption of novel therapies coupled with the favorable reimbursement policies especially in the developed economies has promoted its growth worldwide.

On the contrary, the ignorance symptoms and signs coupled with the high cost of treatment are some of the top barriers vitiating the market growth across the globe. Moreover, the limited availability of FDA approved drugs is estimated to deter the market growth in the long run.

Global Myasthenia Gravis Disease Market: Segmental Analysis

The global myasthenia gravis disease market has been segmented on the basis of treatment, diagnosis, and end-user.

By mode of diagnosis, the global myasthenia gravis disease market has been segmented into blood tests, imaging, edrophonium tests, electrodiagnostic, pulmonary function tests, and others.

By mode of treatment, the global myasthenia gravis disease market has been segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous Hematopoietic Stem Cell Transplantation (HSCT), and others.

By mode of end-users, the global myasthenia gravis disease market has been segmented into clinics, hospitals, academic research institutes, and others.

Reginal Insights

Geographically, the myasthenia gravis disease market span across regions namely, Europe, America, Asia Pacific, and the Middle East and Africa.

Considering the global scenario, the American region is estimated to command the largest market share. The growth is ascribed to the surging number of drug manufacturers, increased government funding for the treatment, and growing awareness regarding the long-term effects of muscle dystrophy. Major companies in this region are launching FDA approved drugs which have augmented the commercial access to such drugs on a global scale.

The European region is considered to occupy the second spot and is likely to retain its pole position in the long run. The growth can be ascribed to the adoption of the latest therapies, high availability of advanced treatment facilities, and the presence of skilled medical professionals.

The Asia Pacific region is estimated to be the fastest growing region due to the presence of a large geriatric population base especially in economies like China and Japan. The surging awareness regarding the long-term effects of muscular dystrophies has further contributed to the market growth. Moreover, the rising awareness regarding neuromuscular disorders coupled with the vast improvement made in the healthcare sector in economies like China, India, Malaysia, and Indonesia has further influenced the market growth to a large extent.

Industry Updates

April 01, 2019: Ra Pharmaceuticals, Inc. has recently declared that the data from its Phase 2 clinical trial of zilucoplan for treating generalized myasthenia gravis has been selected for an Emerging Science dual oral and poster presentation at the American Academy of Neurology Annual Meeting in Philadelphia, 2019.

Competitive Dashboard

The prominent players operating in the global myasthenia gravis disease market comprises AbbVie Inc. (U.S.), F. Hoffmann Roche La Ltd. (Switzerland), Biogen Inc. (U.S.), Fresenius Kabi (Germany), Cipla (India), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Apotex Corporation (Canada), RPG Life Sciences (India), Teva Pharmaceutical Industries Ltd. (Israel), Bristol-Myers Squibb Company (U.S.), Valeant Pharmaceuticals International (U.S.), Novartis Pharmaceuticals Corporation (Switzerland), GlaxoSmithKline plc (UK), and others.

Read Complete Report  with Toc @https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843 

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:                                

Akash Anand                                                                    

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com 

Kidney Dialysis Equipment Market Analysis, Growth Opportunities and Recent Trends by Leading Manufacturers & Region

 Kidney Dialysis Equipment Market Overview

Global kidney dialysis equipment market, as per a report by Market Research Future (MRFR) is touted to register a CAGR of 5.7%, surpassing a valuation of USD 16.5 billion during the forecast period (2018-2023).

Kidney dialysis can be referred to as an artificial technique of maintaining the chemical balance in the blood during kidney failure. Kidneys help to remove body waste, thereby maintaining the blood pressure of the body and create red blood cells, thus ensuring a proper amount of mineral content. Dialysis is the process where the components of the blood are separated by using a semipermeable membrane.

The kidney dialysis equipment market has witnessed a tectonic surge in the past few years, mainly due to the soaring preferences for dialysis over kidney replacement. Factors such as advancing technology and the ever-increase geriatric population are the primary growth stimulants of the market. Advanced technologies in the medical industry are highly encouraging the market growth across the globe. The surging number of dialysis care centers from major players like Davita and Fresenius Medical Care has made treatment available at a much lower cost. This has created new growth opportunities for the market.

On the contrary, the high cost of dialysis, the dearth of compensation, and complications associated with dialysis are some of the major concerns likely to deter the market growth in the years to come.

Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/6302

Global Kidney Dialysis Equipment Market: Segmental Analysis

By type, the market is classified into peritoneal dialysis, hemodialysis, and continuous renal replacement therapy (CRRT). Of these, the hemodialysis segment dominates the market due to surging prevalence of terminal kidney failure among the population.

Based on the apparatus type, the market comprises peritoneal dialysis equipment, hemodialysis equipment, and consumables and continuous renal replacement therapy systems. Of these, the hemodialysis equipment segment is likely to grab the major share mainly due to higher accessibility of HD centers, rising number of community dialysis centers, and improved reimbursement coverage. Also, increased awareness and physician expertise to administer HD, and other related socio-demographic factors are likely to encourage the market growth in the segment.

The end users segment constitutes clinics, hospitals, home care, in-center dialysis settings, and ambulatory services. Of these, the in-center dialysis settings segment acquire the larger share owing to the rising number of dialysis centers worldwide, high availability of healthcare professionals in dialysis centers, and new product launches.

Kidney Dialysis Equipment Market Regional Frontiers

Geographically, the kidney dialysis equipment market spans across the Asia Pacific, North America, Europe, and the Middle East & Africa.

Considering the global scenario, North America is predicted to dominate the global market in terms of revenue share. It is home to some of the leading manufacturers who have specialized the dialysis treatment machines by several intercessions, thereby solving complications. Moreover, the surging healthcare expenditure in Canada has created new growth avenues for the regional market.

The kidney dialysis equipment market in Europe is estimated to acquire the second position, mainly due to soaring expenses on research, declining human health, technological advancements, and surging need for effective and innovative therapies.

The market in the Asia Pacific will witness considerable growth owing to the surging number of dialysis center, increasing number of patient population in the region, and initiatives undertaken by the government in order to produce cost-effective treatment methods. The enhanced healthcare economy in the region will further create better growth ambiance for the kidney dialysis equipment market.

Kidney Dialysis Equipment Industry Updates

September 2019: Almost half a million of the American population is anticipated to live with kidney failure, and the rest continue their dialysis their entire life. Texas hospital is using a new technology that can make treatments comfortable and faster at home. The new device developed has been termed Tablo, and is a portable dialysis machine, designed to work as simple as a smartphone application.

Kidney Dialysis Equipment Market Competitive Dashboard

The top players operating in the kidney dialysis equipment market include Davita Healthcare Partners Inc., Fresenius Medical Care AG & Co. Ka, B. Braun Melsungen AG, Baxter International Inc., Nipro Corporation, Diaverum Deutschland GmbH, Nikkiso Co., Ltd., Nxstage Medical, Inc., Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Corporation). Terumo Corporation, Mar Cor Purification, Inc. (A Cantel Medical Company), Teleflex Incorporated, Rockwell Medical, and Hemoclean CO., LTD.

Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/kidney-dialysis-equipment-market-6302

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

Covid19 Impact on Diagnostic Electrocardiograph (ECG) Market Perspective With Study Of Key Players & Revenue To Steady Growth Forecast To 2023

 The AI in drug discovery market is growing continually. Artificial intelligence technology has the potential to revolutionize the pharmaceutical sector and open whole new avenues for technology providers. Resultantly, the adoption of the AI technology to boost efficiency and throughput in clinician workflow is rising steadily. Moreover, the growing applications of AI technology in various drug discovery and development process escalate the market demand to furthered height. 

Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of AI in drug discovery market 2020 @https://www.marketresearchfuture.com/sample_request/9393

According to Market Research Future (MRFR), the global Artificial Intelligence (AI) in Drug Discovery Market is poised to create a valuation of USD 2,015.1 MN by 2025, registering a massive 40.8% CAGR throughout the predicted years (2019 – 2025). Recent COVID 19 pandemic is projected to boost the size of the market. AI and machine learning integration in discovery and development applications are increasing to expedite drug development processes. 

Also, substantial investments made into AI business are projected to boost the market growth. AI integration minimizes the risk of adverse reactions during trials, reduces the drug discovery timeframe, and, most importantly, reduces drug development costs. Machine learning and other AI tools have a vast potential to make the discovery of new pharmaceuticals faster, cheaper, and more productively. As a result, major pharma companies are increasingly using AI technology for drug discovery. 

Moreover, rising numbers of start-ups operating in the AI spectrum drug discovery foster market growth. Simultaneously, increasing numbers of cross-industry partnerships formed to achieve improvements in drug development outcomes drive the growth of the market. On the other hand, high costs associated with AI integration are a major factor estimated to hamper the market growth. Also, the lack of adequate infrastructure in low economic countries obstructs the growth of the market. 

AI in Drug Discovery Market – Segments

The report is segmented into seven dynamics;

By Product Type    : Services and Software.

By Molecule Type: Large and Small Molecules.

By Technology       : Machine Learning, Deep Learning, and others.

By Indication          : Immuno-oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, and others.

By Application       : Target Identification, Candidate Screening, De novo Drug Designing, Drug Optimization & Repurposing, Preclinical Testing, and others.

By End-User            : Pharmaceutical & Biotechnology Companies, Research Centers and Academic & Government Institutes, Contract Research Organizations, and others.

By Regions               : Americas, Europe, Asia Pacific, and Rest-of-the-World. 

 

AI in Drug Discovery Market – Regional Analysis

North America dominates the global AI in drug discovery market. Market share attributes to the increasing prevalence of chronic diseases and high healthcare expenses. Moreover, the recent COVID 19 pandemic is estimated to increase the size of the regional market. Besides, factors such as the presence of growing numbers of big AI platform developers and a well-developed healthcare sector in the region allow rapid market growth.

Increasing adoption of top AI platforms, including Google AI, Microsoft Azure, and TensorFlow by major pharma companies in drug discovery processes, boost the regional market growth. Moreover, increasing demand for Artificial Intelligence technologies from key pharmaceutical companies such as AbbVie, Genentech, Eli Lilly and Company, and Amgen, among others, drive the growth of the market.

Europe stands second in the global AI in drug discovery market. Market growth is driven by the increasing R&D activities in the pharma sector and the high demand for AI solutions by drug development companies. Top pharma companies in the region form strategic partnerships with international AI service providers to expedite their drug discovery process, which, in turn, boosts the market growth. The UK, Germany, and France are the major growth contributors to the regional market.

Additionally, substantial R&D investments and increasing government funding in the development of AI technology foster regional market growth. Furthermore, the recent COVID 19 epidemic is estimated to increase the size of the regional market. Besides, strategic deals between the UK government and industry players are expected to increase AI research investments. The European AI in the drug discovery market is projected to create a substantial revenue pocket.

The Asia Pacific AI in drug discovery market is estimated to become the fastest-growing market. Factors such as the increasing demand for effective drug discovery solutions and rapidly growing pharmaceutical sectors in the region drive market growth. A number of start-ups in the region are working to integrate AI in drug discovery market . It is predicted that the adoption of AI technologies in mainstream drug discovery protocols will take place in the future. With their increasing numbers of AI platform companies, countries like India and China contribute significantly to the regional market growth.

AI in Drug Discovery Market   - Competitive Analysis

The global AI in drug discovery market appears fiercely competitive & fragmented due to the presence of numerous well-established players. To gain a larger competitive advantage in the market, these players incorporate strategic initiatives such as mergers & acquisitions, collaborations, technology launch, and expansion. Also, AI drug discovery companies make substantial investments to R&D and drive clinical studies.  

Browse Complete Report @ https://www.marketresearchfuture.com/reports/ai-drug-discovery-market-9393

 

Major Players: 

Players leading the global AI in drug discovery market include Microsoft Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Cyclica, Bioage, Numerate, Numedii, Inc., Envisagenics, Twoxar, Incorporated, Owkin, Inc., Xtalpi, Inc., Verge Genomics, and Berg LLC, among others. 

Innovation/Industry/Related News:

June 01, 2020 ---- Syntekabio Inc. (South Korea), a bioinformatics venture firm and AI drug Development Company, announced the identification of a respiratory disease drug as a potential COVID19 therapeutics. The crystal structure of SARS-CoV-2’s 3CL protease (Mpro) is the main viral protease that plays a crucial role in viral gene expression and proliferation of the SARS-CoV-2 virus. As soon as this structural information became available, Syntekabio commenced AI screening using its proprietary AI platform DeepMatcherTM and supercomputer. The company screened 3,000 approved drugs and identified potential COVID-19 therapeutics.

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:       

Akash Anand           

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

 

Artificial intelligence (AI) in Drug Discovery Market Reflect Enormous Growth at a CAGR 40.8% by 2025

 The AI in drug discovery market is growing continually. Artificial intelligence technology has the potential to revolutionize the pharmaceutical sector and open whole new avenues for technology providers. Resultantly, the adoption of the AI technology to boost efficiency and throughput in clinician workflow is rising steadily. Moreover, the growing applications of AI technology in various drug discovery and development process escalate the market demand to furthered height. 

Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of AI in drug discovery market 2020 @https://www.marketresearchfuture.com/sample_request/9393

According to Market Research Future (MRFR), the global Artificial Intelligence (AI) in Drug Discovery Market is poised to create a valuation of USD 2,015.1 MN by 2025, registering a massive 40.8% CAGR throughout the predicted years (2019 – 2025). Recent COVID 19 pandemic is projected to boost the size of the market. AI and machine learning integration in discovery and development applications are increasing to expedite drug development processes. 

Also, substantial investments made into AI business are projected to boost the market growth. AI integration minimizes the risk of adverse reactions during trials, reduces the drug discovery timeframe, and, most importantly, reduces drug development costs. Machine learning and other AI tools have a vast potential to make the discovery of new pharmaceuticals faster, cheaper, and more productively. As a result, major pharma companies are increasingly using AI technology for drug discovery. 

Moreover, rising numbers of start-ups operating in the AI spectrum drug discovery foster market growth. Simultaneously, increasing numbers of cross-industry partnerships formed to achieve improvements in drug development outcomes drive the growth of the market. On the other hand, high costs associated with AI integration are a major factor estimated to hamper the market growth. Also, the lack of adequate infrastructure in low economic countries obstructs the growth of the market. 

AI in Drug Discovery Market – Segments

The report is segmented into seven dynamics;

By Product Type    : Services and Software.

By Molecule Type: Large and Small Molecules.

By Technology       : Machine Learning, Deep Learning, and others.

By Indication          : Immuno-oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, and others.

By Application       : Target Identification, Candidate Screening, De novo Drug Designing, Drug Optimization & Repurposing, Preclinical Testing, and others.

By End-User            : Pharmaceutical & Biotechnology Companies, Research Centers and Academic & Government Institutes, Contract Research Organizations, and others.

By Regions               : Americas, Europe, Asia Pacific, and Rest-of-the-World. 

 

AI in Drug Discovery Market – Regional Analysis

North America dominates the global AI in drug discovery market. Market share attributes to the increasing prevalence of chronic diseases and high healthcare expenses. Moreover, the recent COVID 19 pandemic is estimated to increase the size of the regional market. Besides, factors such as the presence of growing numbers of big AI platform developers and a well-developed healthcare sector in the region allow rapid market growth.

Increasing adoption of top AI platforms, including Google AI, Microsoft Azure, and TensorFlow by major pharma companies in drug discovery processes, boost the regional market growth. Moreover, increasing demand for Artificial Intelligence technologies from key pharmaceutical companies such as AbbVie, Genentech, Eli Lilly and Company, and Amgen, among others, drive the growth of the market.

Europe stands second in the global AI in drug discovery market. Market growth is driven by the increasing R&D activities in the pharma sector and the high demand for AI solutions by drug development companies. Top pharma companies in the region form strategic partnerships with international AI service providers to expedite their drug discovery process, which, in turn, boosts the market growth. The UK, Germany, and France are the major growth contributors to the regional market.

Additionally, substantial R&D investments and increasing government funding in the development of AI technology foster regional market growth. Furthermore, the recent COVID 19 epidemic is estimated to increase the size of the regional market. Besides, strategic deals between the UK government and industry players are expected to increase AI research investments. The European AI in the drug discovery market is projected to create a substantial revenue pocket.

The Asia Pacific AI in drug discovery market is estimated to become the fastest-growing market. Factors such as the increasing demand for effective drug discovery solutions and rapidly growing pharmaceutical sectors in the region drive market growth. A number of start-ups in the region are working to integrate AI in drug discovery market . It is predicted that the adoption of AI technologies in mainstream drug discovery protocols will take place in the future. With their increasing numbers of AI platform companies, countries like India and China contribute significantly to the regional market growth.

AI in Drug Discovery Market   - Competitive Analysis

The global AI in drug discovery market appears fiercely competitive & fragmented due to the presence of numerous well-established players. To gain a larger competitive advantage in the market, these players incorporate strategic initiatives such as mergers & acquisitions, collaborations, technology launch, and expansion. Also, AI drug discovery companies make substantial investments to R&D and drive clinical studies.  

Browse Complete Report @ https://www.marketresearchfuture.com/reports/ai-drug-discovery-market-9393

 

Major Players: 

Players leading the global AI in drug discovery market include Microsoft Corporation, IBM Corporation, Alphabet Inc., Atomwise, Inc., Deep Genomics, Cloud Pharmaceuticals, Inc., Insilico Medicine, BenevolentAI, Exscientia, Cyclica, Bioage, Numerate, Numedii, Inc., Envisagenics, Twoxar, Incorporated, Owkin, Inc., Xtalpi, Inc., Verge Genomics, and Berg LLC, among others. 

Innovation/Industry/Related News:

June 01, 2020 ---- Syntekabio Inc. (South Korea), a bioinformatics venture firm and AI drug Development Company, announced the identification of a respiratory disease drug as a potential COVID19 therapeutics. The crystal structure of SARS-CoV-2’s 3CL protease (Mpro) is the main viral protease that plays a crucial role in viral gene expression and proliferation of the SARS-CoV-2 virus. As soon as this structural information became available, Syntekabio commenced AI screening using its proprietary AI platform DeepMatcherTM and supercomputer. The company screened 3,000 approved drugs and identified potential COVID-19 therapeutics.

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:       

Akash Anand           

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

 

Healthcare Contract Manufacturing Market Demand By Top Companies - Global Analysis to Forecast by 2023

 Market Insights 

A globally growing population and a gradually transforming healthcare sector are witnessing the growth in the healthcare contract manufacturing market. Valued a USD 129.91 billion at the end of 2016, the global Healthcare CMO Market is expected to grow at an above average CAGR of 9.86% during the forecast period of 2017 to 2023. 

The global healthcare sector is undergoing some major changes as new technologies, and various other factors make their mark. The patent expiry of various popular drugs and medical devices is encouraging new players to enter the market, thus increasing competition. Subsequently, the increased competition has compelled leading market players to reform their existing business strategies in order to perpetuate further market growth. In response to growing expenses on R & D and the increased focus of major player on various other core strategies, have boosted the market for healthcare contract manufacturing organizations (CMOs). Additionally, the global demand for effective drugs and medical devices has grown substantially, and in order to meet these demands successfully, major players are turning to contract manufacturing. Emerging economies are expected to be vital in the future of this market due to the high concentration of expertise and increasingly available research & development technologies. These countries offer lower operating costs, comparatively cheap, experienced labor and supportive government bodies that aim to improve the regional healthcare sector. The sanction of Good Manufacturing Practice certificates in emerging economies has contributed considerably to the growth of the healthcare contract manufacturing market. 

The growing cost of R&D and the complexity of the supply chain combined with difficulties regarding control of 3rd parties may hinder market growth during the forecast period. However, the need for product innovation, the growing outsourcing of various other activities such as design, feasibility tests, and validation are expected to provide ample opportunity for growth of the market in the coming years.

Market Segmentation

The global healthcare contract manufacturing market is segmented on the basis of type, service type, industry, and region. By type, the market is segmented into sterile, and nonsterile.The nonsterile segment is growing at the most significant pace and is expected to achieve a CAGR of 10% during the forecast period due to the reduced standards associated with non-sterile contact manufacturing. By service type, the market is segmented into pharmaceutical contract manufacturing services and medical device contract manufacturing services. By industry, the market is segmented into pharmaceutical, medical device, and biopharmaceutical. By region, the global market is segmented into the Americas, Europe, the Asia-Pacific and the Middle East & Africa.

Regional Analysis

The Americas have the most significant share of the global market due to the increased investment in the healthcare sector in this region, particularly in the U.S and Canada. These countries lead the region's growth and have strong economic conditions. The focus of adoption of the latest in technology and the growing demand for effective treatments have to lead to the sophisticated production of pharmaceuticals and medical devices. The use of advanced manufacturing technology and implementation of cost-effective manufacturing models have propelled the region into leading position. The region is expected to reach an estimated USD 102.99 billion by the end of 2023.

Meanwhile, the Asia-Pacific is the fastest growing regional market and is expected to witness a CAGR of 9.97% during the forecast period. The concentration of emerging economies in this region and supportive policies in this region regarding contract manufacturing organizations is expected to encourage growth for the region during the assessment period. The availability of comparatively cheap labor, a supportive structure for R&D activities and the overall reduced operating costs in emerging economies of this region are some key drivers of growth for the healthcare contract manufacturing market.

Key Players

Prominent players that have been analysed in the report include market leaders such as Evonik Industries, Teva Pharmaceutical Industries, Vetter Pharma International, Mylan, Patheon, Sanmina Corporation, Forefront Medical Technologies, Hamilton Company, Flex Ltd., AbbVie, Boehringer Ingelheim, Lonza AG, Catalan, Aesica Pharmaceuticals, Benchmark Electronics, Grifols International S.A., and others.

Latest Industry News

AstraZeneca and Saudi Pharmaceutical Industries & Medical Appliances  Corporations (SPIMACO) have signed an agreement which initiates the launch of the contract manufacturing operation in the KSA.

Orgenisis, a contract manufacturer for advanced cell therapies, has formed a partnership with Great Point Partners, in order to finance and expand Orgenisis contract development business under a newly formed subsidiary called Masthercell Global.

Read More @ https://www.marketresearchfuture.com/reports/healthcare-contract-manufacturing-market-5637

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.